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Hematopoietic stem and progenitor cell (HSPC) transplantation is the best-studied
cellular therapy and successful in vitro control of HSPCs has wide clinical implications.
Nitric oxide (NO) is a central signaling molecule in vivo and has been implicated in HSPC
mobilization to the blood stream in mice. The influence of NO on HSPC behavior in vitro
is, however, largely obscure due to the variety of employed cell types, NO administration
systems, and used concentration ranges in the literature. Additionally, most studies
are based on murine cells, which do not necessarily mimic human HSPC behavior.
Thus, the aim of the present study was the systematic, concentration-dependent
evaluation of NO-mediated effects on human HSPC behavior in vitro. By culture in the
presence of the long-term NO donor diethylenetriamine/nitric oxide adduct (DETA/NO)
in a nontoxic concentration window, a biphasic role of NO in the regulation of HSPC
behavior was identified: Low DETA/NO concentrations activated classical NO signaling,
identified via increased intracellular cyclic guanosine monophosphate (cGMP) levels
and proteinkinases G (PKG)-dependent vasodilator-stimulated phosphoprotein (VASP)
phosphorylation and mediated a pro-proliferative response of HSPCs. In contrast,
elevated NO concentrations slowed cell proliferation and induced HSPC differentiation.
At high concentrations, s-nitrosylation levels were elevated, and myeloid differentiation
was increased at the expense of lymphoid progenitors. Together, these findings hint at a
central role of NO in regulating human HSPC behavior and stress the importance and the
potential of the use of adequate NO concentrations for in vitro cultures of HSPCs, with
possible implications for clinical application of in vitro expanded or differentiated HSPCs
for cellular therapies.
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INTRODUCTION
Tight regulation of proliferation and differentiation is central to blood homeostasis, as its balance
secures the life-long regeneration of the blood system. All types of mature blood and immune
cells arise from one type of multipotent stem cell termed hematopoietic stem cell (HSC) (Rieger
and Schroeder, 2012). By asymmetric cell divisions, HSCs self-renew and generate multipotent
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progenitors (MPPs) that undergo differentiation and
proliferation events to produce all types of mature blood
cells but lack the ability to self-renew indefinitely (Beckmann
et al., 2007). Additionally, HSCs divide symmetrically to expand
the HSC population and ensure the long-term renewal of
the blood system (Seita and Weissman, 2010). With ongoing
differentiation, hematopoietic stem and progenitor cells (HSPCs)
lose their multipotency and are committed to one blood lineage,
which are categorized as lymphoid and myeloid (Goardon et al.,
2011). Human HSPCs are commonly identified by expression
of the surface marker CD34, which is lost on mature blood cells
(Civin et al., 1984). By using additional immunophenotypical
markers, HSPC subsets can be identified via flow cytometry.
As expression of CD38 and CD45RA marks more mature
progenitor cells, the lack of these antigens can be used
additionally to identify HSCs and MPPs (Lansdorp et al., 1990;
Bhatia et al., 1997). During the commitment of lympho-myeloid
progenitors to the lymphoid branch, progenitor cells gradually
lose myeloid potential with increasing expression of the early
B cell marker CD10 (Ichii et al., 2010). Myeloid progenitors
(CD34+ CD38+ CD10−) can be grouped into common myeloid
progenitors (CMPs), granulocyte-macrophage progenitors
(GMPs), and megakaryocyte-erythrocyte progenitors (MEPs) by
their expression of CD135 and CD45RA (Doulatov et al., 2010).
MEPs lack the expression of CD135, while CMPs and GMPs are
both positive for this marker. The transition from CMP to GMP
stage is correlated with the expression of CD45RA.
In adult life, HSC behavior is regulated in the red bonemarrow
by a multitude of signals from neighboring cells, extracellular
matrix components, as well as soluble molecules in a highly
specialized microenvironment called HSC niche (Asada et al.,
2017; Crane et al., 2017; Szade et al., 2018). HSCs are often
found in close proximity of the vasculature (Kiel et al., 2005),
where distinct types of blood vessels form specialized niche areas
(Itkin et al., 2016). A magnitude of signaling molecules has
been identified in the niche, which regulate HSC fate. Among
these, redox species such as reactive oxygen species (ROS) and
nitric oxide (NO) have gained more and more attention (Urao
and Ushio-Fukai, 2013; Ludin et al., 2014; Itkin et al., 2016;
Ramasamy et al., 2016; Passaro et al., 2017).
NO is a short-lived signaling molecule and is predominantly
produced enzymatically in vivo by NO synthases (NOS1,
NOS2, and NOS3) requiring L-arginine as substrate and O2
and reduced nicotinamide adenine dinucleotide phosphate
(NADPH) as cosubstrates. The gasotransmitter NO passes
cellular membranes by free diffusion, interacts with various
intracellular targets depending on its concentration, and
thus activates different signaling pathways. At physiological
concentrations of NO in the picomolar to nanomolar range (Hall
and Garthwaite, 2009), NO primarily interacts with the soluble
guanylyl cyclase (sGC) and activates classical NO signaling
by binding to its heme center. Subsequently, sGC produces
large amounts of cyclic guanosine monophosphate (cGMP),
which targets cGMP-dependent proteinkinases G (PKG) among
others (Ahern et al., 2002). These serine (Ser)/threonine (Thr)
kinases in turn phosphorylate a variety of targets downstream
of NO such as the vasodilator-stimulated phosphoprotein
(VASP). This actin-binding focal adhesion adaptor protein
is implicated in actin reorganization and is predominantly
phosphorylated at Ser239 following PKG activation (Thomson
et al., 2011). At slightly higher concentrations, NO drives specific
posttranslational modifications, termed s-nitrosylation, via the
enzyme-independent addition of a nitroso-group to a protein
thiol (Martinez-Ruiz et al., 2011). This reversible, redox-sensitive
modification has been shown to be implicated in a wide range
of physiological processes, while excessive s-nitrosylation is
thought to mark pathophysiological modifications. At elevated
concentrations NO reacts with other reactive species such as
H2O2 or O
−
2 forming reactive nitrogen species (RNS), which
mediate indirect effects of NO. These are thought to account
for toxic effects of NO and lead to the induction of apoptosis
(Thomas et al., 2008). Due to the short lifetime of the molecule,
NO is a locally acting signaling molecule. While it diffuses away
from its source, its concentration decreases rapidly as it is quickly
oxidized to nitrate and nitrite in aqueous environment.
NO has been identified as a regulator of cell proliferation and
differentiation in a variety of cell types (Lv et al., 2015; Tapia-
Limonchi et al., 2016) and during organ formation in model
organisms (Enikolopov et al., 1999; Peunova et al., 2007). Its
impact on HSPC proliferation and differentiation, however, is
largely obscure due to contradictory findings in the literature.
This originates from a low comparability of the data due to
different approaches of NO generation or inhibition of NO
signaling. Further, examined species, analyzed cell types, and
studied concentration ranges of NO largely differ and thus
strongly compromise the ability to draw definite conclusions. To
complicate matters further, in vivo data generated in mice do
not represent the human system accurately, as NO generation
differs in rodents and humans, e.g., with regard to the inducibility
of NOS2 by inflammatory cytokines and likely with respect
to produced NO concentrations (Schneemann and Schoeden,
2007).Moreover, studies based on the pharmacological inhibition
of NO synthesis or the knockout of NOS isoforms inherently
lack the opportunity to monitor concentration-dependent effects
of NO. This is crucial, however, as NO signaling is highly
concentration dependent. As the HSC niche is comprised of a
complex communication network where various cell types could
act as NO sources and NO could interact with a multitude
of targets to yield indirect effects, direct effects of NO on
human HSPC proliferation and differentiation were monitored
in vitro. By systematic variation in NO levels in a nontoxic
concentration range, NO signaling was mimicked in various
settings such as homeostasis and acute stress. As mode of
NO generation the long-term donor diethylenetriamine/nitric
oxide adduct (DETA/NO)—a diazeniumdiolate—was chosen,
which spontaneously releases 2mol NO per mol of the parent
compound and has a half-life of 20 h under physiological
conditions. This is described to yield a concentration of free
NO, which is estimated to be three orders of magnitude
lower than the parent compound (Pervin et al., 2007). By
covering a wide concentration range of physiologically relevant
concentrations of NO, this study aims to shed light onto the
concentration-dependent effects of NO signaling in human
HSPCs in vitro and to contribute to a better understanding of
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All chemicals, unless otherwise stated, were obtained fromMerck
KGaA, Darmstadt, Germany and used as obtained.
Isolation and in vitro Culture of Human
CD34+ Cells
Human umbilical cord blood was obtained from DKMS cord
blood bank gGmbH (Dresden, Germany) or the cord blood bank
of the German Red Cross Services (Mannheim, Germany) after
informed consent of the parents and approval by the local ethics
committee (Ethik-Kommission der Landesärztekammer Baden-
Württemberg, project number B-F-2013-111). Mononuclear
cells were isolated from cord blood samples up to 48 h after
collection by density gradient centrifugation using lymphocyte
separation medium (PromoCell GmbH, Heidelberg, Germany).
Subsequently, HSPCs were obtained from the mononuclear
cell fraction by positive selection for the cell surface marker
CD34 via magnetic activated cell sorting (MACS, Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany) according to the
manufacturer’s instructions. HSPCs were used for experiments if
the CD34+ cell fraction was at least 95% as determined by flow
cytometry. HSPCs were maintained in Hematopoietic Progenitor
Expansion Medium DXF (PromoCell GmbH, Heidelberg,
Germany) with 1% of Cytokine Mix E (PromoCell GmbH,
Heidelberg, Germany) in a humidified incubator at 37◦C
and 5% CO2.
Stimulation of HSPCs With DETA/NO
DETA/NO stock solutions were made in 0.01M NaOH, and the
optical density (OD) of the intact NO donor was checked at λ
= 252 nm via UV/vis (ε = 7,640 M−1 cm−1). Aliquoted stock
solutions were kept at −80◦C for several days. Before use in
experiments, the concentration of the stock solution was assessed
via UV/vis and further diluted in cool phosphate-buffered saline
(PBS) to 1,000× of the intended concentrations. Cells were
stimulated with 1 µl/ml in cell culture medium. To generate
a prolonged release of NO and avoid accumulation of nitrite
and nitrate as by-products of NO release, a media exchange was
performed daily with stimulation.
Flow Cytometric Analysis of HSPC
Proliferation and Differentiation
HSPCs were stained with 1µM CellTraceTM Violet (CTV,
Thermo Fisher Scientific Inc. Waltham, MA, USA) according
to the manufacturer’s instructions after isolation. HSPCs were
stimulated daily with up to 20µM of DETA/NO. On days 0 and
5, cells were additionally stained for the expression of cell surface
markers using fluorescently labeled antibodies and analyzed by
flow cytometry.
For analysis of cell surface markers 4 × 104 CTV-stained
HSPCs were seeded in 1ml Hematopoietic Progenitor Expansion
Medium DXF (PromoCell GmbH) with 1% of Cytokine Mix
E (PromoCell GmbH) in a 24-well plate and stimulated daily
with up to 20µM of DETA/NO. On days 0 and 5 of culture,
HSPCs were additionally stained with the following antibody
cocktail (clone; dilution): anti-human CD34-PE-Cy7 (581; 1:40),
anti-human CD38-APC-H7 (HB7; 1:20), anti-human CD10-
APC (HI10a; 1:20), anti-human CD45RA-FITC (HI100; 1:5),
and anti-human CD135-PE (4G8, 1:5) (all antibodies from
Becton Dickinson Inc., East Rutherford, NJ, USA) according
to manufacturer’s instructions. 7AAD (1:80; Becton Dickinson
Inc.) was added for the last 10min of antibody incubation.
For discrimination of positive populations, 1% of fluorescence-
minus-one controls (FMO controls) were regarded as false
positive events. Cells were analyzed using the BD FACSVerseTM
flow cytometer with 405, 488, and 640 nm lasers at a flowrate
of 60 µl min−1. Photomultiplier voltages were adjusted using
unstained cells, and fluorescence spillover from one channel into
another was compensated using single-stained controls. For the
analysis of HSPC proliferation and differentiation, FlowJo 7.6.5
(FlowJo LLC, Ashland, OR, USA) was used. Singlet events were
discriminated from aggregates using the pulse-width against area
of the forward scatter (FSC) signal. HSPCs were gated in a dot
plot of the side scatter against the FSC. Proliferation data were
obtained via the CTV signal using the proliferation tool algorithm
in FlowJo, where the CTV signal on day 0 was fixed as peak 0
and the number of generations as well as the variation coefficient
was kept constant for all samples. Cellular events in each cell
generation were used to calculate the fraction of cells in each cell
generation as well as the cell division index. The latter is defined
as the number of cellular divisions divided by the initial cell
number. For the analysis of HSPC differentiation, viable CD34+
cells (7AAD−, CD34+) were categorized into HSCs/MPPs
(7AAD−, CD34+; CD38−, CD45RA−), CLPs (7AAD−, CD34+;
CD10+) and myeloid progenitors (7AAD−, CD34+; CD10−;
CD38+) according to their surface marker expression via
FMO controls. Accordingly, myeloid progenitors were further
divided into CMPs (CD135+, CD45RA−), GMP (CD135+,
CD45RA+), and MEPs (CD135−, CD45RA−) depending on
their expression of CD135 and CD45RA. Cell fractions in
single HSPC populations were exported to GraphPad Prism 6
(GraphPad Software, San Diego, CA, USA) for further analysis.
Due to high interdonor variations, data were additionally
normalized to the solvent control for better comparability.
Mean values of n = 4 independent experiments as well as
the corresponding standard deviations were calculated using
GraphPad Prism and analyzed for significance of intermean
differences via analysis of variance (ANOVA).
Colony Forming Unit Assay
Myeloid progenitor cells were determined retrospectively by a
colony forming unit assay. HSPCs (4 × 104) were seeded in
1ml medium in a 24-well plate and stimulated daily with up
to 20µM DETA/NO for 5 days with daily media exchange.
On days 0 and 5 of culture, 1,500 cells were transferred
to 300 µl of Iscove’s modified Dulbecco’s medium with 2%
fetal bovine serum (Stemcell Technologies Inc., Vancouver,
Canada), mixed thoroughly with 3ml of MethoCult H4434
(Stemcell Technologies Inc.), and plated into 35mm Petri
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dishes in triplicates, which were kept under standard cell
culture conditions for 12 days. The colonies were assessed by
light microscopy (Axio Vert.A1, Carl Zeiss AG, Oberkochen,
Germany) and characterized according to the “Atlas of
Human Hematopoietic Colonies From Cord Blood” (Stemcell
Technologies Inc., Vancouver, Canada).
Competitive Enzyme-Linked Immunoassay
to Determine Intracellular cGMP Levels
Intracellular cGMP levels of HSPCs after stimulation with
DETA/NO were determined using the Cyclic GMP XP R©
Assay Kit (Cell Signaling Technology Inc., Danvers, MA,
USA) following manufacturer’s instructions. After cultivation
at a density of 105 cells × ml−1 for 24 h, 105 cells were
treated with up to 25µM of DETA/NO alone or additionally
pretreated with 25 molar equivalents of 2-4-carboxyphenyl-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (cPTIO) for
10min (compared to the maximal amount of NO released by
DETA/NO). Cells were incubated for 30min at 37◦C and 5%
CO2 after treatment and lysed following the manufacturer’s
instructions using the supplied lysis buffer supplemented with
1mM phenylmethylsulfonyl fluoride and stored at −20◦C.
The assay was performed with the Cyclic GMP XP R© Assay
Kit (Cell Signaling Technology Inc., Danvers, MA, USA) using
40 µl of the lysates or standard together with 40 µl of the
horseradish peroxidase (HRP)-coupled cGMP. For data analysis,
the measured optical density (OD) values at λ = 450 nm, which
correspond to the converted substrate by the HRP-coupled
competitive antigen, were exported to a spreadsheet program
and used for data analysis.
Detection of Protein Phosphorylation via
Western Blotting
After cultivation at a density of 105 cells × ml−1 for 24 h,
105 cells were treated with up to 25µM DETA/NO directly
or stimulated with 10µM DETA/NO and preincubated with
25 molar equivalents of cPTIO for 10min (respective to the
maximal amount of NO released by DETA/NO). After 30min of
stimulation, cells were lysed with lysis buffer [20mM Tris–HCl,
150mM NaCl, 1mM ethylenediaminetetraacetic acid (EDTA),
1mM ethylene glycol tetraacetic acid (EGTA), 1% Triton X-
100] on ice for 15min. Equal protein amounts were mixed
with Laemmli buffer, heated (95◦C, 5min), loaded onto 12%
acrylamide gels, separated by size via sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and blotted
onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad
Laboratories Inc., Hercules, USA) via wet blotting. Membranes
were blocked with 5% bovine serum albumin (BSA) in Tris-
buffered saline (20mM Tris–HCl, 140mM NaCl, pH = 7.6)
with 0.1% Tween 20 (TBST) (1 h, RT) and incubated with
rabbit anti-human VASP phosphoSer239 (polyclonal, 1:2,000;
Cell Signaling Technology Inc., Danvers, MA, USA), mouse
anti-human VASP (43/VASP, 1:1,000; Becton Dickinson Inc.,
East Rutherford, NJ, USA) or mouse anti-human Vinculin
(hVIN-1, 1:400; Merck KGaA, Darmstadt, Germany) at 4◦C
overnight. After extensive washing in TBST, the membranes
were incubated with species-specific, HRP-conjugated secondary
antibodies (1:20,000; Cell Signaling Technology Inc., Danvers,
MA, USA) (1 h, RT). Subsequently membranes were washed
thoroughly in TBST, incubated with the SuperSignalTM West
Femto Maximum Sensitivity substrate (Thermo Fisher Scientific
Inc., Waltham, MA, USA) according to the manufacturer’s
instructions, and the chemiluminescence signal was detected
using a Lumi-ImagerTM F1 detection system (Roche Diagnostics
International AG, Risch, Switzerland). After linear adjustment
of brightness and contrast, grayscale values of the protein
bands were determined in the regions of interest using the gel
analysis tools in ImageJ (https://imagej.nih.gov/ij/index.html).
To determine the signal independent of the protein amount, gray
values of the protein bands of interest were normalized to the
respective loading controls.
Detection of Protein s-Nitrosylation via
Western Blotting
Protein s-nitrosylation of HSPCs after 5 days of stimulation
with up to 20µM of DETA/NO was assessed with the PierceTM
S-Nitrosylation Western Blot Kit (Thermo Fisher Scientific
Inc., Waltham, MA, USA) according to the manufacturer’s
instructions with protein precipitation steps performed
overnight. Chemiluminescence signals of the membranes were
detected using a Lumi-ImagerTM F1 detection system (Roche
Diagnostics International AG, Risch, Switzerland). After linear
adjustment of brightness and contrast, grayscale values of
the protein bands were determined in the regions of interest
using the gel analysis tools in ImageJ (https://imagej.nih.gov/
ij/index.html). To determine the signal independent of the
protein amount, gray values of the protein bands of interest were
normalized to the respective loading controls.
Expression of Nitric Oxide Synthases via
Polymerase Chain Reaction
RNA was isolated from the positive control cell lines HaCat
(obtained by the German Cancer Research Center), CaCo2
(kind gift by Prof. Orian-Rousseau, Karlsruhe Institute of
Technology), and THP-1 (kind gift by Prof. Overhage, former
Karlsruhe Institute of Technology, now: Carlton University,
Canada), the HSPC model cell lines KG1a and TF-1 (both
Leibniz-Institut-Deutsche Sammlung vonMikroorganismen und
Zellkulturen GmbH), freshly isolated human HSPCs derived
from cord blood of five donors, as well as mesenchymal stromal
cells (MSCs) derived from bone marrow (kind gift by Prof.
Bieback, Medical Faculty Mannheim, University Heidelberg)
of three donors using the RNeasy R© Mini Kit (Quiagen
N.V., Venlo, Netherlands) according to the manufacturer’s
instructions. RNA concentration was determined by measuring
the optical density of the obtained samples at λ = 280 nm
via a NanoDropTM 2000 spectrophotometer (Thermo Fisher
Scientific Inc., Waltham, MA, USA). Complementary DNA
(cDNA) was synthesized from the isolated RNA samples applying
the TaqManTM Reverse Transcription Reagents (Thermo Fisher
Scientific Inc., Waltham, MA, USA). Via PCR, specific gene
sections were amplified using the peqGOLD Hot Taq-DNA
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Polymerase Kit and dNTP Set (both VWR International
GmbH, Darmstadt, Germany) as well as specific primers
for NOS1 (forward, CCTCCCGCCCTGCACCATCTT; reverse,
CTTGCCCCATTTCCATTCCTCGTA), NOS2 (forward, TC
CGAGGCAAACAGCACATTCA; reverse, GGGTTGGGGGT
GTGGTGATGT), and NOS3 (forward, CATCTTCAGCCC
CAAACGGA; reverse, AGCGGATTGTAGCCTGGAAC). As a
negative control, a no template control with ultrapure RNase-
free water instead of template was carried along. After heating
to 95◦C for 30 s, DNA sections were amplified in 30 cycles
of denaturation (94◦C; 30 s), annealing (NOS1/NOS3, 60◦C;
NOS2, 62◦C; 30 s), and elongation (72◦C, 90 s) and subsequently
cooled to 4◦C. DNA products were mixed with DNA Gel
loading dye (6x, Thermo Fisher Scientific Inc., Waltham, MA,
USA) and separated via agarose gel electrophoresis in a 2%
(w/v) agarose gel with GelRed
TM
Nucleic Acid Gel Stain
(Biotium, Inc., Hayward, CA, USA). For size determination
of the fragments, the DNA ladder 100 bp as well as 1 kb
plus (VWR International GmbH, Darmstadt, Germany) was
applied. The gels were analyzed using the Lumi-ImagerTM F1
detection system (Roche Diagnostics International AG, Risch,
Switzerland).
Flow Cytometric Analysis of Apoptotic and
Dead Cells via Annexin V and SytoxTM
AADvancedTM (Sytox) Staining to Determine
a Cytocompatible Concentration Range of
DETA/NO
On the day of isolation, 2 × 104 HSPCs were seeded in 500 µl
of cell-specific culture medium in a 48-well plate and stimulated
with up to 500µM DETA/NO. Cells were cultured for 5 days
with daily media renewal and stimulation with the NO donor.
On day 5, the cell number was determined and 2–10 × 104
cells were washed in annexin buffer (10mM HEPES, 140mM
NaCl, 2.5mM CaCl2, pH = 7.4). After centrifugation, the cell
pellet was resuspended in 100 µl annexin buffer with 1µM
SytoxTM AADvancedTM (Sytox, Thermo Fisher Scientific Inc.,
Waltham, MA, USA) and 5 µl Annexin V-FITC (BioLegend
Inc., San Diego, CA, USA) and incubated for 15min at RT
protected from light. After washing with 500 µl annexin
buffer, cells were immediately analyzed by flow cytometry.
Single stain controls, with heat-treated and untreated cells, were
used for compensation. The viable cell fraction (Annexin V−
and Sytox−) was plotted against the decadic logarithm of the
DETA/NO concentration, and the data points were interpolated








Statistical significance of intermean differences was tested
with one-way ANOVA using GraphPad Prism 6 (GraphPad
Software, San Diego, CA, USA). Tests were chosen according
to the requirements of the respective experiment and data
sets. Paired data sets were subjected to one-way ANOVA
with Greenhouse–Geisser correction. When comparing multiple
intermean differences in comparison to a control group,
Dunnett’s test was applied to correct for multiple comparisons.
Additionally, a posttest was applied to test for linearity of
the group means with increasing concentration of the added
compound. When comparing preselected pairs of columns,
Sidak’s test was used to correct formultiple comparisons. P< 0.05
were regarded as indicative for statistically significant differences
between compared groups and are marked by an asterisk (∗)
in the respective figures, P < 0.01 or 0.001 by two asterisks
(∗∗) or three asterisks (∗∗∗), respectively, and P > 0.05 by “ns”
(not significant).
RESULTS
NO Release Influences the Proliferation of
HSPCs in a Concentration-Dependent
Manner
To systematically monitor the concentration-dependent
influence of NO on HSPC proliferation, cells were stained
with CellTraceTM Violet (CTV) after isolation, cultured in the
presence of DETA/NO for 5 days and subsequently analyzed via
flow cytometry. As concentrations up to 20µM of DETA/NO
were well tolerated by HSPCs (Supplementary Figure 1), they
were used for cell stimulation to cover a wide concentration
range of the gasotransmitter. Additional inhibition of inherent
NO synthesis with small molecules was not required in the
present study, as human cord blood-derived HSPCs did not
express NO synthase isoforms (Supplementary Figure 2).
Stimulation with various concentrations of DETA/NO affected
the proliferative activity of HSPCs in a biphasic manner. As
shown in Figure 1A for a representative donor, the CTV signal
was shifted to lower fluorescence intensities at intermediate
DETA/NO concentrations (1 and 5µM) in comparison to
the solvent control, revealing a higher proliferative activity
of HSPCs during culture. In contrast, concentrations above
10µM DETA/NO caused a decreased proliferative activity that
lead to a retention of CTV. Further, at elevated concentrations
of DETA/NO, the emergence of two HSPC subpopulations
of different proliferative activity was observed. This also
manifested itself in the HSPC distribution in the respective cell
generations. Culture with low DETA/NO concentrations had
no significant impact on the distribution of mean cell fractions,
while elevated concentrations starting at 10µM DETA/NO
induced a dramatic change (Figure 1B). At these levels, cell
fractions that underwent one to two cell divisions were increased
at the expense of highly proliferative cells. In addition, HSPCs
that had performed three or four cell divisions were reduced
when treated with 10 or 15µM DETA/NO, respectively. At
20µM DETA/NO, this increase was at the expense of highly
proliferative HSPC fractions, which underwent more than four
cell divisions. This effect was also prominent in the calculated
cell division index. Relative to the solvent control, the index
was significantly reduced to 0.83-fold upon culture in presence
of 10µM DETA/NO (Figure 1C). Higher DETA/NO levels
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FIGURE 1 | Concentration-dependent influence of up to 20µM diethylenetriamine/nitric oxide adduct (DETA/NO) on hematopoietic stem and progenitor cell (HSPC)
proliferation in vitro. (A) Overlay of the CellTraceTM Violet (CTV) fluorescence intensity profiles (x-axis) of one representative donor before (gray, top) and after cultivation
with DETA/NO for 5 days (colored, concentrations increasing from top to bottom). (B) Calculated cell fractions in HSPC generations (y-axis) after 5 days of culture with
DETA/NO (x-axis). Bar graphs indicate the mean cell fraction in single cell generations (indicated by numbers) of n = 4 independent experiments with the
corresponding standard deviation as error bars. (C) Calculated cell division index of CTV-stained HSPCs relative to the solvent control (y-axis) after 5 days of
stimulation with DETA/NO (x-axis). The dot plot displays the relative cell division index of n = 4 independent experiments with the mean and the corresponding
standard deviation shown as line and error bars. (D) Cell number of unstained HSPCs normalized to the solvent control (y-axis) after 5 days of culture in the presence
of DETA/NO (x-axis). The boxplot graph displays the median as a line across the boxes of n = 8 independent experiments and the mean as a plus. Lower and upper
boxes indicate the 25th percentile to the 75th percentile. Whiskers represent maximum and minimum values. Statistically significant intermean differences as per
ANOVA (comparison of (A–C) each column with the control or (D) preselected pairs of columns) are indicated as follows: *P < 0.05; **P < 0.001; ***0.0001 < P <
0.001; ****P < 0.0001.
induced an even stronger decrease (0.55-fold of the control
at 20µM DETA/NO). These findings were complemented by
analysis of the NO-induced proliferative behavior of unstained
HSPCs (Figure 1D). Here, culture conditions of 0.5 and 1µM
DETA/NO lead to a significant increase in cell number to the
1.67- and 1.66-fold relative to the solvent control after 5 days
of culture, while high concentrations of DETA/NO seemed to
have a reductive effect on the cell number. Together, these results
indicate a concentration-dependent effect of NO on human
HSPC proliferation in vitro. Despite the lack of a significant, NO-
induced change in cell proliferation at intermediate DETA/NO
levels, the NO-induced increase in HSPC numbers adds to the
observed pro-proliferative tendencies detected via CTV staining
at these NO levels. Thus, these data support a biphasic role
of NO on HSPC proliferation where low to intermediate NO
concentrations encourage HSPC proliferation while higher levels
slow cell proliferation.
Prolonged NO Release Increases the
Expression Level of CD34 on HSPCs
We next asked which cell types and processes within the applied
HSPC populations were responsible for the observed changes
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in HSPC proliferation: rather HSCs and MPPs indicating that
their maintenance was induced by NO or rather early progenitor
cells, suggesting that differentiation was enhanced in response
to NO. Thus, we additionally monitored the expression of the
HSPC marker CD34 after culture with 5 and 20µM DETA/NO
and compared it to the solvent control. The CD34-PE-Cy 7
fluorescence intensity as a measure of CD34 expression was
increased by treatment with DETA/NO (Figure 2A). Highly
proliferative cell fractions that display low to intermediate CD34
fluorescence intensity when treated with the solvent alone were
shifted to higher CD34 fluorescence intensities with DETA/NO
treatment both at intermediate and high concentrations. To
better quantify this effect, we categorized HSPCs according to
their CD34 expression in CD34high, CD34intemediate, and CD34low
based on the fluorescence intensity in the respective channel
(Figure 2B). CD34high cell fractions were increased significantly
by 1.2- and 1.9-fold compared to the solvent control after
culture with 5 and 20µM DETA/NO, respectively. Accordingly,
DETA/NO treatment decreased CD34low cell fractions to 0.8-
and 0.5-fold of the solvent control at intermediate and high
concentrations (Figure 2C). The increase in CD34 expression
was not distributed equally over the total HSPC population
but differed depending on the proliferative state of the cells
(Figures 2D,E). Compared to the solvent control, intermediate
DETA/NO concentrations induced a significant increase in
CD34-PE-Cy 7 mean fluorescence intensity (MFI) in cell
fractions, which underwent low numbers of cellular divisions.
While at high DETA/NO concentrations, this trend was also
observable, the CD34 MFI increased additionally with increasing
proliferative activity, while cells that underwent three cellular
divisions showed a significant decrease in CD34 MFI to 0.6-
fold compared to the solvent control. This emergence of two
highly CD34 positive subpopulations of different proliferative
state hinted at a NO-induced differentiation of HSPCs rather
than HSC expansion. This hypothesis was also supported by
the observation that both the CD34+ cell fraction and total
CD34 expression levels were reduced after less cell generations
when compared to the control (Supplementary Figure 3). Based
on these observations, we concluded that the concentration-
dependent increase in CD34high expression by DETA/NO could
not have been caused solely by an expansion of HSCs, as this
would have caused a retention of CD34 expression for more
cell generations in comparison to the control. Instead, the data
showed the contrary behavior and additionally hinted toward the
generation of two subpopulations, which strongly express CD34
and proliferate at different rates. We thus hypothesized that NO
affects the differentiation behavior of HSPCs in the culture in
a concentration-dependent manner. To test this, we employed
a multicolor flow cytometry panel and analyzed the different
HSPC subpopulations according to their characteristic antigen
expression profile.
NO Supports Differentiation Into Myeloid
Progenitors in vitro
To analyze NO-mediated effects on HSPC differentiation, the
expression of the cell surface markers CD34, CD38, CD45RA,
CD10, and CD135 was assessed in addition to monitoring the
proliferative behavior by dye dilution of CTV via flow cytometry
(for detailed gating strategy, see Supplementary Figure 4 in
the Supplementary Material). HSCs and MPPs were identified
from vital CD34+ cells using FMO controls as displayed in
Figure 3A. The distinction of HSC and MPP populations
via analysis of CD90 and CD49f coexpression was omitted
in favor of CTV incorporation into the panel due to limited
cell numbers and low expression of CD90 and CD49f in
CD34+ subsets in previous experiments. In the presence of
DETA/NO, a concentration-dependent decrease in HSC and
MPP fractions was observed independent of their proliferative
activity, and a significant reduction to 0.83-fold of the control
was induced by stimulation with 10µM DETA/NO. This
was due to a marked reduction in HSCs and MPPs in HSPC
subsets with low proliferative activity (second generation), while
there was no observable effect in highly proliferative HSPCs
(as exemplified by HSPCs after five cell divisions). Reduced
numbers of HSCs and MPPs with low proliferative activity
could have been caused by an increased proliferation of these
early HSPC types; however, this would have resulted in elevated
HSC and MPP numbers in cell fractions that underwent higher
numbers of cell division. As NO only affected HSC and MPP
numbers in cell fractions that cycled at a low rate without
having any impact on higher proliferative HSC and MPP
fractions, NO seemed to drive HSPCs into differentiation in
a concentration-dependent fashion. CD34+ CD10+ common
lymphoid progenitors (CLPs) were reduced by treatment of
20µM DETA/NO both in weakly and highly proliferative
cell subsets (Figure 3B). Here, CLP fractions were reduced to
0.24- and 0.37-fold of the solvent control in HSPC fractions
that underwent two and five cell divisions, respectively. Early
myeloid progenitor cells were also affected by treatment with
DETA/NO. CMP and GMP fractions increased with rising
concentration of DETA/NO during culture (Figure 4A).
However, MEP cell fractions were not significantly affected by
treatment with DETA/NO in the overall cell population. Yet,
MEP fractions were significantly increased in weakly cycling
HSPCs in a dose-dependent manner, while GMP fractions were
reduced (Supplementary Figure 5A). In HSPC fractions of
higher proliferative activity, MEP fractions were not affected,
while CMP and GMP fractions were increased with increasing
concentration of DETA/NO (Supplementary Figure 5B). This
influence of NO on early myeloid progenitors was only partially
reflected by functional assays. Colony forming unit assays, which
enable the retrospective enumeration of myeloid progenitors,
revealed no significant influence of DETA/NO stimulation on
myeloid colony-forming units (CFUs) due to a high variance
of colony numbers (Figure 4B). Yet, myeloid colony numbers
seemed to rise to a local maximum at culture with 5µM
DETA/NO, which was seen in CFU-GEMM, CFU-G,M,GM,
and BFU-E. At higher concentrations of 15 and 20µM, myeloid
colony numbers were reduced to solvent control levels. Taken
together, these observations support the hypothesis that NO
affects the differentiation behavior of HSPCs in a concentration-
dependent manner. Rather than supporting HSC and MPP
expansion NO seems to act as a concentration-dependent
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FIGURE 2 | Effect of hematopoietic stem and progenitor cell (HSPC) culture in presence of diethylenetriamine/nitric oxide adduct (DETA/NO) for 5 days on the
expression of the HSPC marker CD34 as analyzed by flow cytometry. (A) Pseudo-colored, smoothed dot plots of the fluorescence intensity in the CD34 channel
(y-axis) shown against the CellTraceTM Violet (CTV) channel (x-axis) for one representative donor after culture in presence of 0, 5, and 20µM of DETA/NO. Expression
levels of CD34 were categorized in CD34high, CD34intermediate, and CD34low depending on the displayed fluorescence intensity as indicated. (B) CD34high and (C)
CD34low cell fractions (y-axis) after culture with 0, 5, and 20µM of DETA/NO (x-axis). Bar graphs display the mean cell fractions of n = 4 independent experiments
with the corresponding standard deviations as error bars. Effect of stimulation with (D) 5µM and (E) 20µM DETA/NO on the expression level of CD34 in cells of
different proliferative activity. The y-axis displays the mean fluorescence intensity (MFI) in the CD34 channel relative to the solvent control, while on the x-axis, the
solvent control (control) as well as the number of cellular divisions are shown indicated as generations. Dot plots display the mean of n = 4 independent experiments
with corresponding standard deviations as lines with error bars. Statistically significant intermean differences as per ANOVA (comparison of each column with the
control) are indicated as follows: *P < 0.05; **P < 0.001.
driver of differentiation. At the highest tested concentrations
of DETA/NO, differentiation into lymphoid progenitors was
markedly reduced, while highly proliferative myeloid cell
fractions were supported. In functional assays, however,
these myeloid progenitors showed a decreased CFU-
forming activity.
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FIGURE 3 | Influence of up to 20µM diethylenetriamine/nitric oxide adduct (DETA/NO) on the retention of hematopoietic stem cell (HSC) and multipotent progenitor
(MPP) fractions and the differentiation behavior into early lymphoid progenitor populations in vitro as determined by flow cytometry. Fractions of (A) CD34+ CD38−
CD45RA− HSC and MPP fractions and (B) CD34+ CD10+ CLP fractions (y-axis) relative to the solvent control after 5 days of culture in presence of DETA/NO in the
overall hematopoietic stem and progenitor cell (HSPC) population regardless of their proliferative activity (left) and in cell fractions that underwent two (middle) and five
(right) cell divisions. Boxplot graphs display the median as a line across the boxes of n = 4 independent experiments with mean values indicated by a plus. Lower and
upper boxes indicate the 25th to the 75th percentile. Whiskers represent maximum and minimum values. Statistically significant intermean differences as per ANOVA
(comparison of each column with the control) are indicated as follows: *P < 0.05; **P < 0.001; ***0.0001 < P < 0.001.
NO Activates Predominantly Classical
Signaling Pathways at Low and
Intermediate Levels
To check, whether the effect of NO on HSPC proliferation and
differentiation was mediated by classical or nonclassical
pathways, we monitored the activation of the classical
NO signaling by two independent assays. The intracellular
concentration of the second messenger cGMP was monitored
via a competitive enzyme-linked immunoassay, where the
analyte is subjected to analysis together with an enzyme-
linked competitor antigen. Low intracellular concentrations
of cGMP, therefore, cause high enzymatic conversion of the
substrate, leading to high detected absorption values and
vice versa. Treatment with up to 25µM DETA/NO caused
a decline in absorption beginning at 1µM DETA/NO and
thus revealed an increase in intracellular cGMP in HSPCs
above this concentration (Figure 5A). Mean absorbance values
were significantly reduced in comparison to the control at
concentrations above 10µM DETA/NO. Pretreatment of the
cells with the stochiometric NO scavenger cPTIO reverted
this effect, proving that the increase in cGMP was caused
specifically by the release of NO (Figure 5B). To additionally
monitor classical NO signaling, VASP phosphorylation by
PKG at Ser239 was analyzed as a downstream signaling
event. By treatment of HSPCs with increasing concentrations
of DETA/NO, VASP phosphorylation at Ser239 increased
significantly (Figures 5C,E). In addition, this phosphorylation
event was seen at concentrations as low as 0.5µM DETA/NO
and thus at lower concentrations than indicated by competitive
immunoassays. At low concentrations, specific phosphorylation
of VASP at Ser239 was observed without phosphorylation at
the second PKG phosphorylation site Ser157 (which causes
an apparent shift in molecular weight when separated via
SDS-PAGE). Pretreatment of HSPCs with cPTIO reduced the
VASP phosphorylation at Ser239 significantly compared to the
positive control (Figures 5D,F) and thus proved the specific
phosphorylation of VASP downstream of NO. Beside classical
signaling, NO can also act via posttranslational modification of
protein thiols, termed s-nitrosylation (Figure 5G). Therefore, we
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FIGURE 4 | Concentration-dependent effect of up to 20µM diethylenetriamine/nitric oxide adduct (DETA/NO) on myeloid differentiation of human hematopoietic stem
and progenitor cells (HSPCs) in vitro. (A) Myeloid cell fractions relative to the solvent control (y-axis) as determined immunophenotypically by flow cytometry
depending on the used concentration of DETA/NO in the culture (x-axis). Myeloid progenitors were identified in the CD34+ CD38+ CD10− HSPC subset by their
differential expression of CD135 and CD45RA, where CMPs, GMPs, and MEPs were CD135+ CD45RA−, CD135+ CD45RA+, and CD135− CD45RA−, respectively.
(B) Myeloid progenitors as determined by a colony-forming unit (CFU) assay. The number of colonies per 500 plated cells (y-axis) is shown dependent on the
DETA/NO concentration during culture (x-axis). Boxplot graphs display the median as a line across the boxes of n = 4 independent experiments with the mean shown
as a plus. Lower and upper boxes indicate the 25th to the 75th percentile. Whiskers represent maximum and minimum values. Statistically significant intermean
differences as per ANOVA (posttest for linear trend of the group means) are indicated as follows: *P < 0.05.
analyzed the presence of these modification events by an indirect
labeling method. Enhanced s-nitrosylation events were detected
in HSPC lysates after treatment with high concentrations
such as 10µM of DETA/NO (data from representative donor
shown in Figure 5H, additional data and quantification given in
Supplementary Figure 6). Together, these findings lead to the
conclusion that DETA/NO activates classical NO signaling at
low concentrations in the employed DETA/NO concentration
range but is only detectable at these low concentrations after
sufficient signal amplification along the signaling pathway.
High concentrations of DETA/NO additionally lead to the
modification of protein thiols by nitrosylation, an event that is
thought to function in nonclassical NO signaling.
DISCUSSION
NO is a central regulator of a variety of cellular processes at
low concentrations, while elevated levels mediate toxic effects
by unspecific protein and DNA modifications. Based on in
vitro assays, physiologically relevant NO concentrations prevail
below 50 nM, while toxic effects mediated by nitrosative stress
were observed above 1µM NO (Thomas et al., 2015). In
contrast, human HSPCs were found to be more sensitive toward
exogenous stimulation with NO in the present study. While
concentrations up to 20µM DETA/NO were well tolerated by
HSPCs, higher concentrations induced toxic effects, indicating
a threshold concentration of approximately 20 nM free NO
in HSPCs according to a widely used approximation (Pervin
et al., 2001, 2007). Thus, apoptosis processes seem to be
regulated more tightly in human HSPCs than in cancer cell
lines often employed in early in vitro studies (Thomas et al.,
2004). As the induction of apoptosis is central to avoid the
accumulation of DNA damage in the presence of high levels
of reactive species (such as ROS and RNS) and thus to lower
the chance of malign transformation, apoptosis processes are
strictly regulated in stem cells (Biechonski et al., 2018). In vivo,
the physiologically relevant concentration range of free NO is
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FIGURE 5 | Nitric oxide (NO) signaling in human hematopoietic stem and progenitor cells (HSPCs) after in vitro culture with diethylenetriamine/nitric oxide adduct
(DETA/NO). Activation of classical NO signaling was detected via intracellular cyclic guanosine monophosphate (cGMP) levels by a competitive enzyme-linked
immunoassay. Substrate conversion was measured by absorbance and inversely correlates with intracellular cGMP levels. (A) Absorbance values relative to the
(Continued)
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FIGURE 5 | control (y-axis) shown for up to 25µM DETA/NO (x-axis). (B) Absorbance values (y-axis) after stimulation with 25µM DETA/NO and/or preincubation with
the NO scavenger cPTIO (x-axis). Classical NO signaling was further analyzed by vasodilator-stimulated phosphoprotein (VASP) phosphorylation at Ser239 as shown
by a representative protein immunoblot after stimulation with (C) up to 20µM DETA/NO and (D) 10µM DETA/NO and/or after preincubation with cPTIO (Vinculin as a
loading control). Gray values of VASP phosphorylation at Ser239 relative to the solvent control derived from protein immunoblots after stimulation of HSPCs with (E)
up to 20µM DETA/NO and (F) 10µM DETA/NO and/or preincubation with DETA/NO. (G) Schematic illustration of NO-mediated signaling via the classical NO
signaling pathway and s-nitrosylation. (H) Representative protein immunoblot of s-nitrosylation sites (marked by iodoTMT) after 5 days culture with up to 20µM
DETA/NO (Vinculin as loading control). Dot plots display the mean of n = 3 independent experiments with corresponding standard deviations as lines with error bars.
Statistically significant intermean differences as per ANOVA (comparison of each column with the control) are indicated as follows: *P < 0.05; **P < 0.001. Curved
brackets show linear trends with ***0.0001 < P < 0.001.
estimated to be between 100 pM and 5 nM (Hall and Garthwaite,
2009). Therefore, in the present study, concentrations from
0.1 up to 20µM DETA/NO—corresponding to 0.1–20 nM free
NO—were employed to monitor the full range of NO-mediated
effects on human HSPC behavior both during homeostasis and
under acute stress.
The role of NO as a regulator of cell proliferation has been
thoroughly discussed in the literature both in physiological
and pathological settings such as tumor development and
angiogenesis (Ridnour et al., 2005, 2006, 2008; Villalobo, 2006;
Napoli et al., 2013; Thomas et al., 2015). Although findings
are often contradictory due to the variety of used test systems
and employed NO concentration ranges, a consensus has
been reached where low NO concentrations favor proliferation,
whereas high NO concentrations mediate antiproliferative
and toxic effects (Napoli et al., 2013). Nevertheless, there
are exceptions to this rule depending on the monitored
cell type. Regarding HSPCs, little information is available
to date. Using NO scavengers in vitro (Kashiwakura et al.,
1998) and pharmacological inhibitors for NO synthesis in
vivo (Michurina et al., 2004), an antiproliferative effect of
NO was demonstrated on murine HSPCs. Similar effects
were observed using human bone marrow-derived CD34+
cells in vitro (Maciejewski et al., 1995). Earlier publications
often overestimated physiological concentrations of NO and
thus employed toxic NO concentrations. An essential role of
NO for murine HSPC proliferation was found in NOS3−/−
mice (Aicher et al., 2003) and by exogenous stimulation
of bone marrow-derived mononuclear cells (Krasnov et al.,
2008). Further, NO mediated stress-induced expansion of
HSCs in zebrafish (Hall et al., 2012) and acted as a pro-
proliferative signaling cue in in vitro co-culture models
with macrophages (Luo et al., 2018). Taken together, these
publications argue for NO as a proliferative stimulus in
HSPC biology and hint at NO as a supporter of HSPC
self-renewal but are mainly based on results obtained from
murine systems.
In the present study a wide concentration range of NO was
chosen to allow monitoring the influence of NO on human
HSPC proliferation in a concentration-dependent manner in
vitro. Low concentrations of DETA/NO led to a highly
reproducible increase in HSPC numbers in unstained cells and
a donor-dependent increase in proliferation in CTV-stained
cells supporting a pro-proliferative role of NO in human
HSPC proliferation at low concentrations in vitro. Similar
observations were made in murine HSPCs upon exogenous
stimulation with a NO donor (Nogueira-Pedro et al., 2014).
As low DETA/NO concentrations were activating classical NO
signaling as observed via VASP phosphorylation at Ser239, an
involvement of this pathway in the pro-proliferative response of
HSPCs seems likely. This pathway also mediates the increased
proliferation of murine neural stem cells upon exogenous
stimulation with DETA/NO (Carreira et al., 2013). Little is
known on the possible targets of pro-proliferative NO signaling
under physiological conditions. Using cancer cell lines, cGMP-
independent targets of NO signaling that are involved in cell
cycle regulation and mitogenic signaling have been identified
(Kumar et al., 2010; Batista et al., 2013); however, these findings
might be difficult to transfer to primary cells from healthy
donors, as regulatory proteins of the cell cycle are often
deregulated in cancer cells (Diaz-Moralli et al., 2013). Thus,
the low concentrations that were mediating pro-proliferative
effects argue for the involvement of classical NO signaling,
as s-nitrosylation events require higher concentrations of NO
(Martinez-Ruiz et al., 2011). Consistently, s-nitrosylation events
were solely observed when stimulating human HSPCs with
increased concentrations of DETA/NO in vitro. At these elevated
DETA/NO levels, human HSPC proliferation was slowed in the
present study. This was, however, not attributed to NO-mediated
toxic effects such as cell cycle arrest or induction of apoptosis,
as HSPCs were actively cycling even at highest DETA/NO
concentrations and showed vital morphology. Antiproliferative
effects of NO were also observed during the differentiation
of human peripheral blood-derived CD34+ cells into dendritic
cells (Tiribuzi et al., 2013). Further, NO acts as a switch,
which limits proliferation and induces differentiation in various
types of stem cells (Beltran-Povea et al., 2015; Bonafe et al.,
2015; Tapia-Limonchi et al., 2016) as well as during organ
development in model organisms (Peunova et al., 2007). As CTV
analysis additionally revealed the emergence of twoHSPC subsets
with distinct proliferative activities, an NO-induced change in
HSPC differentiation seemed likely, as distinct differentiation
states are associated with changes in proliferative activity
(Passegue et al., 2005).
Via flow cytometry an NO-induced increase in CD34
expression was seen. This was, however, not caused by the
NO-induced expansion of HSCs and MPPs, as exogenous
stimulation with the gasotransmitter was not attributed to a
prolonged retention of CD34 over more HSPC generations.
Rather, both the CD34 expression level and the CD34+ cell
fraction dropped at an earlier generation compared to the
control. In addition, HSC and MPP cell fractions were reduced
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with increasing concentrations of DETA/NO. Based on these
findings, exogenous stimulation of human HSPCs with NO
acted as a cue for the differentiation into distinct HSPC
subpopulations, which differ both in their CD34 expression
level and in their proliferative activity. Similar observations
were made in the literature by inhibition of NOS isoforms
(Michurina et al., 2004). With rising DETA/NO levels, an
increased myeloid differentiation was observed, which was at
cost of CLPs at highest DETA/NO concentrations. Interestingly,
CMP fractions were increased in highly proliferative subsets,
while MEP fractions were amplified in a subset that underwent
little cell divisions. As MEPs are highly CD34+ (Attar, 2014),
they likely caused the increase in CD34+ cell fractions in early
cell generations upon stimulation with DETA/NO, while the
increase in CMPs and GMPs could have contributed to the NO-
induced high CD34 expression in later cell generations. This
is supported by the fact that HSPC subsets are characterized
by distinct proliferative states with GMPs, CMPs, and MEPs
showing highest, intermediate, and lowest proliferative activity,
respectively (Passegue et al., 2005). In the murine system,
NO-induced differentiation of HSPCs was observed frequently
(Nogueira-Pedro et al., 2014; Jalnapurkar et al., 2016; Luo
et al., 2018), and also in human CD34+ cells, cGMP analogs
were shown to induce increased erythroid differentiation at
the expense of early myeloid progenitors upon activation
of classical NO signaling (Ikuta et al., 2016). Interestingly,
observations via analysis of immunophenotypical markers were
not mirrored completely in functional assays. Consistent with
an NO-induced effect on all types of myeloid progenitors
identified via flow cytometry, no single colony type was
increased in CFU assays. Rather, a trend to increased myeloid
colony numbers was observed at intermediate DETA/NO
concentrations, and colony numbers seemed reduced at high
DETA/NO concentrations (15–20µM) for all myeloid colony
types. These observations hint at the increase in functional
myeloid progenitors at intermediate DETA/NO concentrations,
while the increase in myeloid progenitors at high DETA/NO
concentrations seemed to be correlated with either a loss of
functionality in vitro or a later stage of myeloid differentiation
resulting in reduced CFU numbers. At those high DETA/NO
concentrations, increased levels of s-nitrosylation were detected.
While low concentrations up to 5µM DETA/NO were not
correlated with increased s-nitrosylation, elevated levels of
the modification were detected upon stimulation with 10µM
DETA/NO or above. These cGMP-independent modifications
have been shown to mediate NO-induced increase in CD34
(Jalnapurkar et al., 2016) and CXCR4 expression (Zhang et al.,
2007) on murine and human HSPCs, respectively. In vivo,
these modifications are mediated by cellular mechanisms that
ensure their specificity. In contrast, NO exhibits a diverse
activity toward thiols in vitro, and modifications seem to
occur in a less regulated manner (Wynia-Smith and Smith,
2017). As the increase in s-nitrosylation correlated with
an increased myeloid differentiation of HSPCs, which was
accompanied by a decreased potential to form myeloid colonies,
concentrations above 10µM DETA/NO could drive unspecific
protein modifications in vitro and thus mimic unspecific s-
nitrosylation as present under acute stress. As highest employed
DETA/NO concentrations of 20µM were close to toxic NO
concentrations with beginning induction of apoptosis in some
donors, we expect that effects seen at this highest concentration
could have been partially mediated by apoptotic processes
and could mimic acute stress responses. The present study
identified several concentration ranges of NO, which induced a
variety of cellular responses emphasizing the importance of used
concentrations of the gasotransmitter (Figure 6). Contradictory
findings in the literature are thus likely derived from the high
variance of used NO concentration ranges and NO donors.
Further, results obtained by the knockout or inhibition of NO
synthesis do not allow for the concentration-dependent analysis
of NO signaling.
The cellular redox state is linked to central HSPC behavior
such as proliferation or differentiation (Ludin et al., 2014).
ROS are, on the one hand, correlated with cell cycle arrest
and apoptosis when critical concentrations are reached but are
generally required for regular differentiation of HSCs (Ludin
et al., 2014). Similar to the effects observed in the present
study for NO, elevated concentrations of ROS are linked to
increased myeloid differentiation. Due to their reactive nature,
observed effects of ROS and NO-mediated effects overlap. The
onset of differentiation, marked by a decrease in HSC and
MPP fractions, was however already observed at intermediate
DETA/NO concentrations where increased s-nitrosylation was
not detected. Thus, classical NO signaling could also have
contributed to this effect. Likewise, molecules of the classical NO-
signaling pathway such as cGMP were shown to influence HSPC
differentiation by the modulation of several transcription factors
(Ikuta et al., 2016).
In vivo NO supports HSC retention, while elevated
concentrations lead to HSPC expansion and mobilization
(Chigaev et al., 2011; Nogueira-Pedro et al., 2014; Gur-Cohen
et al., 2016). As the NO-induced mobilization of HSPCs is
correlated with the modulation of VLA4 affinity in vivo,
observed effects at intermediate to high concentrations of
DETA/NO could mimic HSPC mobilization under acute stress.
Together with the egress from the endosteal niche in the bone
marrow to the vascular niche, HSCs that become metabolically
active are prone to myeloid differentiation (Kopp et al., 2005).
Neighboring niche elements such as endothelial cells, specialized
stroma cells, as well as mature hematopoietic cells could serve
as possible sources of targeted NO generation and stimulate
HSPCs in a paracrine manner. Close to sinusoidal blood vessels,
megakaryocytes are often found, which could be a potential
source of NO and which are colocalized with myeloid-primed
HSCs (Pinho et al., 2018). In addition to the regulation of HSCs
via the CXC motif chemokine 4 (Pinho et al., 2018), NO could
be a factor, which influences HSCs in a direct or indirect manner
and, depending on the concentration and duration of the signal,
mediates the NO-induced mobilization and differentiation of the
cells. Similar to the murine system, NO could act as a switch in
the human HSC niche to balance HSC retention in the niche and
mobilization of HSPCs to the blood system.
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FIGURE 6 | Schematic illustration of observed hematopoietic stem and progenitor cell (HSPC) responses after 5 days culture in the presence of the long-term NO
donor diethylenetriamine/nitric oxide adduct (DETA/NO) in vitro (used concentrations and released levels of NO indicated by y-axis on the left side). NO-mediated
signaling, which was detected in specific concentration ranges, is listed in the gray box with the concentration ranges illustrated by color-coded bars. Observed
NO-mediated effects are specified in the yellow box (middle, statistically nonsignificant trends are displayed in italic), while a possible biological context for the
observed effects is given in the green box (right side).
CONCLUSION/SUMMARY
NO has been discussed as a central signaling molecule in
cell proliferation and differentiation in a variety of cell types
both in vivo and in vitro. Regarding HSPCs, no clear picture
was available due to the variety of used cell types, employed
concentration ranges of NO, or the large variation in regard
to experimental design in the literature. Complicating matters
further most studies were based on the murine system, which
differs (at least in some aspects) from the human system in regard
to NO synthesis. In the present study, we could demonstrate
that the influence of NO on human HSPC proliferation and
differentiation is highly dependent on its concentration. At
low concentrations, NO induced a proliferative response of
HSPCs, which might play a role in vivo in HSPC expansion
and mobilization. This effect was likely based on classical
NO signaling pathways, which were shown to be activated
even at lowest used DETA/NO concentrations. At intermediate
levels, NO slowed the proliferation of HSPCs and induced
differentiation, which was in favor of early myeloid progenitors
at highest concentration correlating with increased levels of
s-nitrosylation. These responses might be relevant in stress-
induced myelopoiesis where HSPCs differentiate to meet the
increased demand of myeloid progenitors. Therefore, different
concentrations of NO might be used to induce proliferation
or differentiation in human HSPC culture in vitro. Thus, the
present study paves the way for further evaluation of the potential
of NO for controlled expansion or guided differentiation of
human HSPCs in vitro, which would be beneficial for many
cellular therapies.
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